Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
444 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Novartis AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Novartis AG - Product Pipeline Review - 2014', provides an overview of the Novartis AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Novartis AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Novartis AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Novartis AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Novartis AG's pipeline products Reasons to buy - Evaluate Novartis AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Novartis AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Novartis AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Novartis AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novartis AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Novartis AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Novartis AG Snapshot 9 Novartis AG Overview 9 Key Information 9 Key Facts 9 Novartis AG - Research and Development Overview 10 Key Therapeutic Areas 10 Novartis AG - Pipeline Review 29 Pipeline Products by Stage of Development 29 Pipeline Products - Monotherapy 30 Pipeline Products - Combination Treatment Modalities 31 Pipeline Products - Partnered Products 32 Pipeline Products - Out-Licensed Products 34 Novartis AG - Pipeline Products Glance 36 Novartis AG - Late Stage Pipeline Products 36 Novartis AG - Clinical Stage Pipeline Products 40 Novartis AG - Early Stage Pipeline Products 45 Novartis AG - Unknown Stage Pipeline Products 49 Novartis AG - Drug Profiles 50 (vildagliptin + metformin hydrochloride) 50 ceritinib 51 erismodegib 53 EXE-844 56 haemophilus influenzae type b vaccine 57 meningococcal group B vaccine (rDNA, component, adsorbed) 58 panobinostat 60 pasireotide LAR 66 secukinumab 68 serelaxin 72 imatinib mesylate 75 influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 77 (indacaterol + glycopyrrolate) 79 (sacubitril + valsartan) 81 aliskiren fumarate 83 bimagrumab 85 binimetinib 87 binimetinib + encorafenib 91 buparlisib hydrochloride 92 canakinumab 96 encorafenib 100 everolimus 101 fingolimod hydrochloride 105 glycopyrrolate 108 influenza [(H1N1) + (H3N2) + B/Massachusetts/2/2012] (surface antigen inactivated) vaccine 110 influenza vaccine (quadrivalent) 111 LCI-699 112 LEE-011 113 midostaurin 115 nilotinib 117 omalizumab 120 oxytocin 122 pasireotide 124 pradigastat sodium 127 ranibizumab 128 rufinamide 131 siponimod 133 zoledronic acid 135 dovitinib lactate 137 (VAK-694 + QAX-576) 140 aldesleukin 141 alisporivir 143 AQW-051 145 BCT-197 147 BGJ-398 148 BGS-649 149 BHQ-880 150 BPS-804 152 BVS-857 153 BYL-719 154 CAD-106 156 CFZ-533 158 cipargamin 159 EDP-239 160 EXE-844b 161 FCR-001 162 fevipiprant 164 HSC-835 165 iloperidone 166 INC-280 168 KAF-156 170 KRP-203 171 LCL-161 173 LFF-269 175 LFF-571 176 LFG-316 178 LIK-066 180 luminespib 181 mavoglurant 184 MCS-110 186 meningococcal vaccine (serogroups A, B, C, Y and W-135) (pentavalent) 187 octreotide acetate long acting 188 pandemic influenza vaccine [H5N1] 189 patupilone 190 QAL-964 192 QAX-576 193 QBM-076 195 QBW-251 196 QGE-031 197 ruxolitinib phosphate 199 seasonal influenza vaccine (trivalent) 203 selurampanel 204 streptococcus vaccine [serogroup A] (trivalent) 205 tisagenlecleucel-T 206 VAK-694 208 VAY-736 210 Vi-CRM197 212 BPR-277 213 BZF-961 214 CFG-920 215 CGF-166 216 CJM-112 217 CLR-457 218 EGF-816 219 LEZ-763 220 LGH-447 221 LGK-974 221 LJM-716 223 RAF-265 225 sotrastaurin acetate 226 1790GAHB Vaccine 228 ABL-001 229 Cell Therapy to Target CD19 for Oncology 230 Cell Therapy to Target EGFR for Glioblastoma 231 CGM-097 232 diphtheria + pertussis + tetanus vaccine 233 EDP-239 + alisporivir 234 HDM-201 235 HIV vaccine 236 influenza [H7N9] (monovalent) vaccine 237 influenza vaccine [H3N2] (monovalent) 238 LEQ-506 239 LFA-102 240 LFX-453 242 LHW-090 243 LOP-628 244 MesoCART 245 NOV-8 246 octreotide acetate LAR 247 Small Molecule For Respiratory Diseases 249 staphylococcus aureus vaccine 250 TAP-311 251 meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine 252 Alphavirus Replicons 253 BQS-481 254 BVB-808 255 candida vaccine 256 CART-123 257 Cell Therapy for Autoimmune Myocarditis 258 Cell Therapy Program for Cancer 259 cosyntropin ER 260 ESK-1 261 GNF-776 262 GNFPf-5069 263 HG-78501 264 IMP-701 265 Kartogenin 266 LCZ-960 267 LGB-321 268 meningococcal meningitis vaccine 269 Monoclonal Antibody Conjugated 2 for Cancer 270 Monoclonal Antibody Conjugated 3 for Cancer 271 Monoclonal Antibody for Undisclosed Indication 272 NIBR-0213 273 NITD-349 274 NVPTNKS-656 275 Small Molecule to Agonize GPR119 for Type II Diabetes 276 Small Molecule to Inhibit LRRK2 for Parkinsons Disease 277 Small Molecule to Inhibit OX2R for Insomnia 278 Small Molecules to Antagonize CSF1R for Cancer and Osteolysis 279 Small Molecules to Inhibit Dipeptidyl Peptidase IV for Diabetes 281 streptococcus vaccine 282 Antibodies to Inhibit CTLA4 and PD-1 for Cancer 283 GNFPf-5179 284 GNFPf-5466 285 LJH-685 286 Small Molecules 1 for Undisclosed Indication 287 Small Molecules 2 for Undisclosed Indication 288 Small Molecules for Malaria 289 Small Molecules for Tuberculosis 290 Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 291 Small Molecules to Inhibit CFTR for Secretory Diarrhea 292 Small Molecules to Inhibit PI4KIIIbeta for HCV 293 west nile vaccine 294 Antibody to Inhibit PD-L1 for Cancer 295 Antibody to Inhibit TIM-3 for Cancer 296 LQN-725 297 PCA-062 298 Small Molecules for Mycobacterium Tuberculosis 299 typhoid and paratyphoid fever vaccine 300 Novartis AG - Pipeline Analysis 301 Novartis AG - Pipeline Products by Target 301 Novartis AG - Pipeline Products by Route of Administration 306 Novartis AG - Pipeline Products by Molecule Type 307 Novartis AG - Pipeline Products by Mechanism of Action 309 Novartis AG - Recent Pipeline Updates 317 Novartis AG - Dormant Projects 386 Novartis AG - Discontinued Pipeline Products 393 Discontinued Pipeline Product Profiles 395 Novartis AG - Company Statement 408 Novartis AG - Locations And Subsidiaries 410 Head Office 410 Other Locations & Subsidiaries 410 Appendix 430 Methodology 430 Coverage 430 Secondary Research 430 Primary Research 430 Expert Panel Validation 430 Contact Us 431 Disclaimer 431
List of Tables Novartis AG, Key Information 22 Novartis AG, Key Facts 22 Novartis AG - Pipeline by Indication, 2014 25 Novartis AG - Pipeline by Stage of Development, 2014 42 Novartis AG - Monotherapy Products in Pipeline, 2014 43 Novartis AG - Combination Treatment Modalities in Pipeline, 2014 44 Novartis AG - Partnered Products in Pipeline, 2014 45 Novartis AG - Partnered Products/ Combination Treatment Modalities, 2014 46 Novartis AG - Out-Licensed Products in Pipeline, 2014 47 Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 48 Novartis AG - Pre-Registration, 2014 49 Novartis AG - Filing rejected/Withdrawn, 2014 50 Novartis AG - Phase III, 2014 51 Novartis AG - Phase II, 2014 53 Novartis AG - Phase I, 2014 56 Novartis AG - IND/CTA Filed, 2014 58 Novartis AG - Preclinical, 2014 59 Novartis AG - Discovery, 2014 61 Novartis AG - Unknown, 2014 62 Novartis AG - Pipeline by Target, 2014 315 Novartis AG - Pipeline by Route of Administration, 2014 319 Novartis AG - Pipeline by Molecule Type, 2014 321 Novartis AG - Pipeline Products by Mechanism of Action, 2014 323 Novartis AG - Recent Pipeline Updates, 2014 330 Novartis AG - Dormant Developmental Projects,2014 399 Novartis AG - Discontinued Pipeline Products, 2014 406 Novartis AG, Other Locations 423 Novartis AG, Subsidiaries 423
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
